Tenatoprazole
Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003. The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories.
Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007 and again in 2012.
Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.
